BACKGROUND: Persistent @entity281 with high-risk @entity1082 ) is a predominant cause of @entity5 , and HPV58 is the third most common virus detected in the @entity1 with @entity5 in Asia. E6 and E7 are the viral oncogenes which are constitutively expressed in HPV-associated @entity5 cells and can be used as target antigens for related immunotherapy. In this study, we modified the HPV58 E6 and E7 oncogenes to eliminate their oncogenic potential and constructed a recombinant DNA vaccine that coexpresses the sig-HPV58 mE6E7-Fc- @entity10611 fusion antigen in addition to @entity2304 ( @entity2304 ) and @entity8271 as molecular adjuvants (PVAX1-HPV58 mE6E7FcGB) for the treatment of HPV58 (+) @entity5 . METHODS: PVAX1-HPV58 mE6E7FcGB recombinant DNA vaccine was constructed to express a fusion protein containing a signal peptide, a modified HPV58 mE6E7 gene, and human IgG Fc and @entity4495 ( @entity10611 )-anchoring sequences using the modified DNA vaccine vector PVAX1-IRES-GM/ @entity8271 that coexpresses @entity2304 , and @entity8271 . C57BL/6 @entity19 were challenged by HPV58 E6E7-expressing B16-HPV58 E6E7 cells, followed by immunization by PVAX1-HPV58 mE6E7FcGB vaccine on days 7, 14, 21 after @entity5 challenge. The cellular immune responses in immunized @entity19 were assessed by measuring IFN-y production in splenocytes upon stimulation by HPV58 E6E7-GST protein and the lysis of B16-HPV58 E6E7 target cells by splenocytes after restimulation with HPV58 E6E7-GST protein. The antitumor efficacy was evaluated by monitoring the growth of the @entity5 . RESULTS: PVAX1-HPV58 mE6E7FcGB elicited varying levels of IFN-lsgdB58 @entity65071 T-cell immune responses and lysis of target cell in @entity19 in response to the recombinant antigen HPV58 E6E7-GST. Furthermore, the vaccine also induced antitumor responses in the HPV58 (+) B16-HPV58 E6E7 @entity5 challenge model as evidenced by delayed @entity5 development. CONCLUSION: The recombinant DNA vaccine PVAX1-HPV58 mE6E7FcGB efficiently generates cellular immunity and antitumor efficacy in immunized @entity19 . These data provide a basis for the further study of this recombinant vaccine as a potential candidate vaccine.

A DNA vaccine encoding mutated HPV58 mE6E7-Fc- @entity10611 fusion antigen and XXXX and @entity8271 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2304 :: ('12981(Tax:10090)', 'Gene') :: ['GM-CSF', 'granulocyte-macrophage colony-stimulating factor'] @entity65071 :: ('11027', 'Species') :: ['onn'] @entity10611 :: ('CHEBI:59682', 'Chemical') :: ['GPI'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'cervical cancer'] @entity8271 :: ('12519(Tax:10090)', 'Gene') :: ['B7.1'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV'] @entity4495 :: ('MESH:D017261', 'Chemical') :: ['glycosylphosphatidylinositol']
@entity2304 :: (12981(Tax:10090),Gene) :: ['GM-CSF']
